Novo Nordisk rumoured to have blockbuster drug in development  

The Danish medical group is developing a new drug for Type 2 diabetes that could achieve billion dollar sales

Nordea Securities, which forms part of the Nordic banking group Nordea, says that the renowned Danish medical group Novo Nordisk has a potential blockbuster drug under development which could earn a fortune for the company. The term "blockbuster" is only used by analysts and the pharmaceutical industry for new products which are expected to achieve sales of at least USD 1 billion (approx. DKK 7 billion).


Novo Nordisk’s drug candidate – codenamed nn2211 – is a treatment for Type 2 diabetes, which used to be called maturity onset diabetes but is now seen at a rapidly increasing rate in younger generations. In terms of drug development nn2211 is currently at the end of phase 2 testing. Before summer Novo Nordisk is expected to announce whether it will take the drug into final phase 3 tests in humans.


nn2211 is the only drug which is based on the human endocrine substance Glucagon-like Peptide-1(GLP-1). Novo Nordisk hopes that GLP-1 will block the breakdown of beta cells in pancreas where insulin is produced, perhaps stabilising the level and in the best case stimulating the formation of new insulin producing beta cells. The news is reported in daily newspaper Jyllands-Posten.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×